natgillin/translations-raw huggingface dataset:
Porcilis PCV M Hyo contains porcine circovirus type 2 (PCV2) subunit antigen (a protein derived from part of the virus) and an inactivated (killed) strain of Mycoplasma hyopneumoniae bacteria. 
Zdravilo Porcilis PCV M Hyo vsebuje podenoto antigena prašičjega cirkovirusa tipa 2 (PCV2) (beljakovine, pridobljene iz dela virusa) in inaktiviran (neživ) sev bakterije Mycoplasma hyopneumoniae.
What is Porcilis PCV M Hyo and what is it used for? 
Kaj je zdravilo Porcilis PCV M Hyo in za kaj se uporablja?
What benefits of Porcilis PCV M Hyo have been shown in studies? 
Kakšne koristi je zdravilo Porcilis PCV M Hyo izkazalo v študijah?
Laboratory studies in pigs showed that with two-dose vaccination the vaccine had its full effect against PCV2 by 18 days after first injection and against Mycoplasma hyopneumoniae by three weeks after the second injection, whilst with single-dose vaccination the vaccine had its full effect against PCV2 by two weeks and against Mycoplasma hyopneumoniae by four weeks. 
Laboratorijske študije pri prašičih so pokazale, da je cepivo pri cepljenju z dvema odmerkoma svoj polni učinek proti virusu PCV2 doseglo v 18 dneh po prvi injekciji, proti bakteriji Mycoplasma hyopneumoniae pa v treh tednih po drugi injekciji.
Porcilis PCV M Hyo is a veterinary vaccine used to protect pigs against two separate infections, caused by porcine circovirus and Mycoplasma hyopneumoniae. 
Zdravilo Porcilis PCV M Hyo je cepivo za uporabo v veterinarski medicini, ki se uporablja za zaščito prašičev pred dvema različnima okužbama, tj. prašičjim cirkovirusom ini bakterijo Mycoplasma hyopneumoniae.
With two-dose vaccination, protection against PCV2 starts at 18 days after the first injection and for Mycoplasma hyopneumoniae it starts 3 weeks after the second injection. 
Pri cepljenju z dvema odmerkoma nastopi zaščita proti virusu PCV2 18 dni po prvem injiciranju, zaščita proti bakteriji Mycoplasma hyopneumoniae pa nastopi tretji teden po drugem injiciranju.
How is Porcilis PCV M Hyo used? 
Kako se zdravilo Porcilis PCV M Hyo uporablja?
The withdrawal period for Porcilis PCV M Hyo is zero days. 
Karenca za cepivo Porcilis PCV M Hyo je nič dni.
With single-dose vaccination, protection against PCV2 starts at two weeks after the injection and for Mycoplasma hyopneumoniae it starts four weeks after the injection. 
Pri cepljenju z enkratnim odmerkom nastopi zaščita proti virusu PCV2 dva tedna po injiciranju, zaščita proti bakteriji Mycoplasma hyopneumoniae pa nastopi četrti teden po injiciranju.
For both vaccination schedules protection lasts for 22 weeks after (the last) injection for PCV2 and for 21 weeks after (the last) injection for Mycoplasma hyopneumoniae. 
Pri obeh shemah cepljenja traja zaščita proti virusu PCV2 22 tednov od (zadnjega) injiciranja, zaščita proti bakteriji Mycoplasma hyopneumoniae pa traja 21 tednov od (zadnjega) injiciranja.
With both vaccination schedules protection lasted 22 weeks after (the last) injection for PCV2 and 21 weeks after (the last) injection for Mycoplasma hyopneumoniae. 
Pri obeh shemah cepljenja je zaščita proti virusu PCV2 trajala 22 tednov od (zadnje) injekcije, proti bakteriji Mycoplasma hyopneumoniae pa 21 tednov od (zadnje) injekcije.
How does Porcilis PCV M Hyo work? 
Kako zdravilo Porcilis PCV M Hyo deluje?
Date of first authorisation: 11/11/2016 
Datum prve odobritve: 11. november 2016
- If you are pregnant or trying to become pregnant. 
- če ste noseči ali želite zanositi.
Food delayed absorption by approximately 1 hour, and increased plasma exposure by 20 to 30%. 
Hrana je upočasnila absorpcijo za približno 1 uro in povečala izpostavljenost v plazmi za 20 do 30 %.
- If you have heart failure which has recently become worse. 
- če imate srčno popuščanje, ki se je pred kratkim poslabšalo.
Women that need treatment with ivabradine should stop breastfeeding, and choose for another way of feeding their child. 
Ženske, ki potrebujejo zdravljenje z ivabradinom, naj prenehajo z dojenjem ter izberejo drug način hranjenja otroka.
- If you are a woman able to have children and not using reliable contraception. 
- če ste ženska v rodni dobi in ne uporabljate zanesljive kontracepcije.
Name and address of the manufacturer responsible for batch release S.C. Zentiva S.A 
Ime in naslov izdelovalca, odgovornega za sproščanje serij S.C. Zentiva S.A.
- Severe hypotension (< 90/50 mmHg). 
- huda hipotenzija (< 90/50 mm Hg).
- If you are allergic to ivabradine or any of the other ingredients of this medicine (listed in section 6). 
- če ste alergični na ivabradin ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Do not use this medicine after the expiry date which is stated on the label and carton after “EXP”. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu poleg oznake “EXP”.
Tablets must be taken orally twice daily, i.e. once in the morning and once in the evening during meals (see section 5.2). 
Tablete morajo bolniki jemati peroralno dvakrat na dan, to je eno zjutraj in eno zvečer med obrokom (glejte poglavje 5.2).
In this way Ivabradine Zentiva helps to control and reduce the number of angina attacks. 
Na ta način Ivabradin Zentiva pripomore k nadzoru in zmanjševanju anginoznih napadov.
- If you suffer from very low blood pressure. 
- če imate zelo nizek krvni tlak.
• Cisapride (against the gastro-oesophageal reflux). 
• cisaprid (proti gastroezofagealnemu refluksu).
The total clearance is about 400 mL/min and the renal clearance is about 70 mL/min. 
Skupni očistek znaša približno 400 ml/min in ledvični približno 70 ml/min.
- If you are suffering from cardiogenic shock (a heart condition treated in hospital). 
- če imate kardiogeni šok (bolezen srca, ki zahteva zdravljenje v bolnišnici).
They generally occur within the first two months of treatment after which they may occur repeatedly and resolve during or after treatment. 
Navadno se pojavijo v prvih dveh mesecih zdravljenja, nato se lahko občasno ponavljajo ter izginejo med ali po zdravljenju.
Under physiological conditions, ivabradine is rapidly released from tablets and is highly water-soluble (> 10 mg/mL). 
V fizioloških pogojih se ivabradin hitro sprošča iz tablet in je zelo topen v vodi (> 10 mg/ml).
032266 Bucharest Romania 
032266 Bucharest Romunija
If you forget to take a dose of Ivabradine Zentiva, take the next dose at the usual time. 
Če ste pozabili vzeti odmerek zdravila Ivabradin Zentiva, vzemite naslednji odmerek ob običajnem času.
- If you have symptoms such as tiredness, dizziness or shortness of breath (this could mean that your heart is slowing down too much). 
- če opažate simptome, kot so utrujenost, vrtoglavost ali zasoplost (to bi lahko pomenilo, da se vaše srce preveč upočasnjuje).
- If you have had a recent stroke (cerebral attack). 
- če ste nedavno imeli možgansko kap (možganski napad).
However, in postmarketing experience, cases of impaired driving ability due to visual symptoms have been reported. 
V obdobju trženja zdravila pa so poročali o primerih zmanjšane sposobnosti vožnje zaradi simptomov motenj vida.
The following adverse reactions have been reported during clinical trials and are ranked using the following frequency: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data). 
V kliničnih študijah so poročali o naslednjih neželenih učinkih, ki so razvrščeni po naslednji pogostnosti: zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000); zelo redki (<1/10.000); neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
- Sino-atrial block. 
- sinoatrijski blok.
- If you suffer from unstable angina (a severe form in which chest pain occurs very frequently and with or without exertion). 
- če imate nestabilno angino pektoris (hudo obliko, pri kateri se bolečine v prsih pojavljajo zelo pogosto, med naporom ali brez njega).
If you think that the effect of Ivabradine Zentiva is too strong or too weak, talk to your doctor or pharmacist. 
Če menite, da je učinek zdravila Ivabradin Zentiva premočan ali prešibak, se posvetujte z zdravnikom ali farmacevtom.
Ivabradine Zentiva is not intended for use in children and adolescents younger than 18 years. 
Otroci Zdravilo Ivabradin Zentiva ni namenjen za uporabo pri otrocih in mladostnikih, mlajših od 18 let.
The calendar printed on the blister containing the tablets should help you remember when you last took a tablet of Ivabradine Zentiva. 
Koledar, ki je natisnjen na pretisnem omotu s tabletami, vam pomaga, da si zapomnite, kdaj ste nazadnje vzeli tableto zdravila Ivabradin Zentiva.
- Rifampicin (an antibiotic). 
- rifampicin (antibiotik).
- Cardiogenic shock. 
- kardiogeni šok.
No data are available in patients with creatinine clearance below 15 mL/min. 
Za bolnike z očistkom kreatinina pod 15 ml/min ni podatkov.
Hazard Ratio [95% CI] 
razmerje tveganja [95% interval zaupanja]
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
- preobčutljivost na zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1.
• Anti-malarial medicines (such as mefloquine or halofantrine). 
• zdravila proti malariji (na primer meflokin ali halofantrin).
Atrial fibrillation - cardiac arrhythmias 
Atrijska fibrilacija - srčne aritmije
Combination with calcium channel blockers 
Kombinacija z zaviralci kalcijevih kanalčkov
• Bepridil (to treat angina pectoris). 
• bepridil (proti angini pektoris).
- If you suffer from symptoms of atrial fibrillation (pulse rate at rest unusually high (over 110 beats per minute) or irregular, without any apparent reason, making it difficult to measure). 
- če imate simptome atrijske fibrilacije (nenavadno visok srčni utrip v mirovanju (nad 110utripov na minuto) ali brez posebnega vzroka nereden srčni utrip, ki ga je težko izmeriti).
If you are pregnant and have taken Ivabradine Zentiva, talk to your doctor. 
Če ste noseči in ste jemali zdravilo Ivabradin Zentiva, se posvetujte z zdravnikom.
- If your resting heart rate before treatment is too slow (below 70 beats per minute). 
- če je vaša srčna frekvenca med mirovanjem pred zdravljenjem prepočasna (manj kot 70 utripov na minuto).
Pharmacotherapeutic group: Cardiac therapy, other cardiac preparations; ATC code: C01EB17. 
Farmakoterapevtska skupina: zdravila za bolezni srca, druga zdravila za bolezni srca; oznaka ATC: C01EB17.
- If you suffer from uncontrolled blood pressure, especially after a change in your antihypertensive treatment. 
- če imate nenadzorovan krvni tlak, še posebno po zamenjavi zdravljenja zvišanega krvnega tlaka.
The European Medicines Agency has waived the obligation to submit the results of studies with ivabradine in all subsets of the paediatric population for the treatment of angina pectoris. 
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z zdravilom Ivabradin Zentiva za vse podskupine pediatrične populacije za zdravljenje angine pektoris.
The antianginal and anti-ischaemic efficacy of ivabradine was preserved in diabetic patients (n = 457) with a similar safety profile as compared to the overall population. 
Antianginozni in antiishemični učinek ivabradina se je ohranjal pri bolnikih s sladkorno boleznijo (n = 457) s podobnim profilom varnosti kot pri celotni populaciji.
The results on the primary endpoint are mainly driven by the heart failure endpoints, hospitalisation for worsening heart failure (absolute risk reduced by 4.7%) and deaths from heart failure (absolute risk reduced by 1.1%). 
Rezultat končnega izida je izmerjen predvsem na podlagi izidov srčnega popuščanja, hospitalizacij zaradi poslabšanj srčnega popuščanja (absolutno zmanjšanje tveganja za 4,7 %) in umrljivosti zaradi srčnega popuščanja (absolutno zmanjšanje tveganja za 1,1 %).
Ivabradine is eliminated with a main half-life of 2 hours (70 - 75% of the AUC) in plasma and an effective half-life of 11 hours. 
Ivabradin se izloča z glavno razpolovno dobo 2 uri (70 do 75 % površine pod krivuljo (AUC)) v plazmi in efektivno razpolovno dobo 11 ur.
Tablets are available in packs of 14, 28, 56, 84, 98, 100, 112 film-coated tablets. 
Tablete so na voljo v pakiranjih, ki vsebujejo 14, 28, 56, 84, 98, 100, 112 filmsko obloženih tablet.
The safety and efficacy of ivabradine for the treatment of chronic heart failure in children aged below 18 years have not been established. 
Varnost in učinkovitost ivabradina pri zdravljenju kroničnega srčnega popuščanja pri otrocih, mlajših od 18 let, nista bili dokazani.
Crospovidone Magnesium stearate 
Jedro: manitol krospovidon magnezijev stearat
mefloquine, halofantrine, pentamidine, cisapride, intravenous erythromycin). 
meflokin, halofantrin, pentamidin, cisaprid, eritromicin intravensko).
- Pregnancy, lactation and women of child-bearing potential not using appropriate contraceptive measures (see section 4.6). 
- nosečnost, dojenje in ženske v rodni dobi, ki ne uporabljajo zanesljivih kontracepcijskih metod (glejte poglavje 4.6).
The European Medicines Agency has waived the obligation to submit the results of studies with ivabradine in children aged 0 to less than 6 months for the treatment of chronic heart failure. 
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z zdravilom Ivabradin Zentiva za otroke od 0 do manj kot 6 mesecev starosti za zdravljenje kroničnega srčnega popuščanja.
Patients received standard care including beta-blockers (89%), ACE inhibitors and/or angiotensin II antagonists (91%), diuretics (83%), and anti-aldosterone agents (60%). 
Bolniki so prejemali standardno zdravljenje, ki je vključevalo antagoniste adrenergičnih receptorjev beta (89 %), zaviralce ACE in/ali antagoniste angiotenzina II (91 %), diuretike (83 %) in antagoniste aldosterona (60 %).
- If you suffer from severe heart failure or heart failure with abnormality of ECG called “bundle branch block”. 
- če imate hudo srčno popuščanje ali srčno popuščanje z nepravilnostjo EKG, ki se imenuje 'kračni blok'.
Ivabradine Zentiva mainly works by reducing the heart rate by a few beats per minute. 
Ivabradin Zentiva deluje predvsem tako, da znižuje srčno frekvenco za nekaj utripov na minuto.
OPA/Alu/PVC-Alu blisters, paper carton. 
OPA/Alu/PVC-Alu pretisni omoti, kartonska škatla.
- If your heartbeat is exclusively imposed by your pacemaker. 
- če vam srčni utrip narekuje izključno vaš srčni spodbujevalnik.
Very common Luminous phenomena (phosphenes) Common 
Očesne bolezni zelo pogosti pojavi svetlikanja (fosfeni)
14 film-coated tablets 28 film-coated tablets 56 film-coated tablets 84 film-coated tablets 98 film-coated tablets 100 film-coated tablets 112 film-coated tablets 
14 filmsko obloženih tablet 28 filmsko obloženih tablet 56 filmsko obloženih tablet 84 filmsko obloženih tablet 98 filmsko obloženih tablet 100 filmsko obloženih tablet 112 filmsko obloženih tablet
Ivabradine is not effective in the treatment or prevention of cardiac arrhythmias and likely loses its efficacy when a tachyarrhythmia occurs (e.g. ventricular or supraventricular tachycardia). 
Ivabradin ni učinkovit pri zdravljenju ali preprečevanju srčnih aritmij in verjetno izgubi učinkovitost ob pojavu tahiartimij (na primer ventrikularne ali supraventrikularne tahikardije).
Symptoms Overdose may lead to severe and prolonged bradycardia (see section 4.8). 
Simptomi Preveliko odmerjanje lahko privede do hude in podaljšane bradikardije (glejte poglavje 4.8).
- Barbiturates (for difficult sleeping or epilepsy). 
- barbiturate (proti nespečnosti ali epilepsiji).
- In patients with left ventricular dysfunction (left ventricular ejection fraction (LVEF) between 30 and 45%), ivabradine did not have any deleterious influence on LVEF. 
- pri bolnikih z disfunkcijo levega prekata (iztisnim deležem levega prekata med 30 in 45 %) ivabradin ni imel nobenih škodljivih učinkov na iztisni delež levega prekata.
• Pentamidine (an antiparasitic medicine). 
• pentamidin (zdravilo proti parazitom).
Ivabradine has been studied in clinical trials involving nearly 45,000 participants. 
Povzetek varnostnega profila Ivabradin so proučevali v kliničnih študijah, ki so vključile skoraj 45.000 bolnikov.
- Unstable or acute heart failure. 
- nestabilno ali akutno srčno popuščanje.
- If you suffer from a heart rhythm disorder. 
- če imate motnje srčnega ritma.
If any of the above applies to you, talk straight away to your doctor before or while taking Ivabradine Zentiva. 
Če karkoli od naštetega velja za vas, se takoj pogovorite z zdravnikom pred jemanjem zdravila Ivabradin Zentiva ali med njim.
Fertility Studies in rats have shown no effect on fertility in males and females (see section 5.3). 
Plodnost Študije na podganah niso pokazale učinka na plodnost pri samcih in samicah (glejte poglavje 5.3).
• Intravenous erythromycin (an antibiotic). 
• eritromicin v žilo (antibiotik).
Lack of benefit on clinical outcomes in patients with symptomatic chronic stable angina pectoris 
Pomanjkanje koristi na klinične izide pri bolnikih s simptomatsko kronično angino pektoris
Concomitant use with precautions 
Sočasno jemanje ob previdnostnih ukrepih
Contents of the pack and other information What Ivabradine Zentiva contains 
Vsebina pakiranja in dodatne informacije Kaj vsebuje Ivabradin Zentiva
- Resting heart rate below 70 beats per minute prior to treatment. 
- srčna frekvenca med mirovanjem pod 70 utripov na minuto pred zdravljenjem.
- If you suffer from chronic eye retinal disease. 
- če imate kronično bolezen mrežnice očesa.
However, in the absence of extensive data, non-urgent DC-cardioversion should be considered 24 hours after the last dose of ivabradine. 
Toda ker ni obsežnejših podatkov, razmislite o neurgentni kardioverziji z enosmernim tokom v 24 urah po zadnjem odmerku ivabradina.
Pharmacokinetic/pharmacodynamic (PK/PD) relationship PK/PD relationship analysis has shown that heart rate decreases almost linearly with increasing ivabradine and S 18982 plasma concentrations for doses of up to 15 - 20 mg twice daily. 
Farmakokinetično/farmakodinamično (PK/PD) razmerje Analiza razmerja med farmakokinetiko in farmakodinamiko je pokazala, da se srčna frekvenca znižuje skoraj linearno s povečevanjem koncentracije ivabradina in S 18982 v plazmi ob odmerkih do 15 do 20 mg dvakrat na dan.
The most common symptoms of heart failure are breathlessness, fatigue, tiredness and ankle swelling. 
Najpogostejši simptomi srčnega popuščanja vključujejo zasoplost, slabotnost, utrujenost in otekanje gležnjev.
Ivabradine Zentiva may cause temporary luminous visual phenomena (a temporary brightness in the field of vision, see “Possible side effects”). 
Zdravilo Ivabradin Zentiva lahko povzroča začasne vidne pojave svetlikanja (prehodno povečanje svetlosti v vidnem polju, glejte “Možni neželeni učinki”).
- Unstable angina. 
- nestabilna angina pektoris.
These data are consistent with the pharmacological effect of ivabradine related to its interaction with hyperpolarisationactivated Ih currents in the retina, which share extensive homology with the cardiac pacemaker If current. 
Ti podatki so skladni s farmakološkim učinkom ivabradina, povezanim z njegovim medsebojnim delovanjem z mrežničnimi hiperpolarizacijsko sproženimi tokovi Ih, ki si delijo obširno homologijo s srčnim frekvenčno urejevalnim tokom If.
- If you suffer from mild to moderate low blood pressure. 
- če imate blago do zmerno znižan krvni tlak.
The impact of renal impairment (creatinine clearance from 15 to 60 mL/min) on ivabradine pharmacokinetic is minimal, in relation with the low contribution of renal clearance (about 20%) to total elimination for both ivabradine and its main metabolite S 18982 (see section 4.2). 
Učinek ledvične okvare (očistek kreatinina od 15 do 60 ml/min) na farmakokinetiko ivabradina je minimalen, kar je povezano z majhnim prispevkom ledvičnega očistka (približno 20 %) k skupnemu izločanju tako ivabradina kot njegovega poglavitnega presnovka S 18982 (glejte poglavje 4.2).
When pregnant animals were treated during organogenesis at exposures close to therapeutic doses, there was a higher incidence of foetuses with cardiac defects in the rat and a small number of foetuses with ectrodactylia in the rabbit. 
Ko so breje živali zdravili med organogenezo pri izpostavljenostih, ki so bile blizu terapevtskim odmerkom, so opazili večjo pojavnost fetusov s srčnimi napakami pri podganah in majhno število fetusov z ektrodaktilijo pri kuncih.
The PK/PD relationship of ivabradine in paediatric chronic heart failure patients aged 6 months to less than 18 years is similar to the PK/PD relationship described in adults. 
PK/PD razmerje ivabradina pri pediatričnih bolnikih s kroničnim srčnim popuščanjem, starih od 6 mesecev do manj kot 18 let, je podobno PK/PD razmerju, ki so ga opisali pri odraslih.
The potent CYP3A4 inhibitors ketoconazole (200 mg once daily) and josamycin (1 g twice daily) increased ivabradine mean plasma exposure by 7 to 8-fold. 
Močna zaviralca citokroma P450 3A4 ketokonazol (200 mg enkrat na dan) in josamicin (1 g dvakrat na dan) sta povečala srednjo izpostavljenost ivabradinu v plazmi za 7- do 8-krat.
In particular, the additional benefit over 5 mg twice daily was established in a reference-controlled study versus atenolol: total exercise duration at trough was increased by about 1 minute after one month of treatment with 5 mg twice daily and further improved by almost 25 seconds after an additional 3-month period with forced titration to 7.5 mg twice daily. 
Večji koristni učinek od odmerka 5 mg dvakrat na dan so zlasti dokazali v referenčni kontrolirani študiji v primerjavi z atenololom: skupno trajanje vadbe v času najmanjšega učinka se je povečalo za približno 1 minuto po enem mesecu zdravljenja z odmerkom 5 mg dvakrat na dan in še nadalje izboljšalo za skoraj 25 sekund po dodatnem 3mesečnem obdobju z obveznim titriranjem na 7,5 mg dvakrat na dan.
The pharmacokinetic profile of ivabradine in paediatric chronic heart failure patients aged 6 months to less than 18 years is similar to the pharmacokinetics described in adults when a titration scheme based on age and weight is applied. 
Farmakokinetični profil ivabradina pri pediatričnih bolnikih s kroničnim srčnim popuščanjem, starih od 6 mesecev do manj kot 18 let, je podoben farmakokinetičnim lastnostim, ki so opisane pri odraslih bolnikih, ko se uporablja shema titriranja, ki temelji na starosti in telesni masi bolnika.
In some cases (e.g. if you are elderly), your doctor may prescribe half the dose i.e., one half 5 mg tablet of Ivabradine Zentiva 5 mg (corresponding to 2.5 mg ivabradine) in the morning and one half 5 mg tablet in the evening. 
Nekaterim bolnikom (na primer, če ste starejši) lahko zdravnik predpiše polovični odmerek, se pravi eno polovico 5 mg tablete (kar ustreza 2,5 mg ivabradina) zjutraj in eno polovico 5 mg tablete zvečer.
At usual recommended doses, heart rate reduction is approximately 10 bpm at rest and during exercise. 
Ob običajnih priporočenih odmerkih znižanje srčne frekvence znaša približno 10 utripov na minute med mirovanjem in vadbo.
Ivabradine Zentiva should be taken during meals. 
Zdravilo Ivabradin Zentiva morate jemati med obrokom.
No dose adjustment is required in patients with renal insufficiency and creatinine clearance above 15 mL/min (see section 5.2). 
Pri bolnikih z ledvično okvaro in očistkom kreatinina nad 15 ml/min odmerka ni potrebno prilagajati (glejte poglavje 5.2).
The average plasma concentration is 10 ng/mL (CV = 38%) at steady-state. 
Povprečna koncentracija v plazmi znaša 10 ng/ml (koeficient variacije = 38 %) v stanju dinamičnega ravnovesja.
Ivabradine is indicated only for symptomatic treatment of chronic stable angina pectoris because ivabradine has no benefits on cardiovascular outcomes (e.g. myocardial infarction or cardiovascular death) (see section 5.1). 
Ivabradin je indiciran samo za simptomatsko zdravljenje kronične stabilne angine pektoris, ker nima koristi na srčno-žilne izide (npr. miokardni infarkt ali srčno-žilno smrt) (glejte poglavje 5.1).